促性腺激素释放激素激动剂治疗对骨代谢新标志物的影响。

Effect of treatment with GnRH agonists on new markers of bone metabolism.

作者信息

Kukuvitis A, Bildiris J, Prapas Y, Tsamis D, Papadimas J, Dimitriadou A, Vlassis G

机构信息

4th Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Greece.

出版信息

Gynecol Obstet Invest. 1999;47(3):194-6. doi: 10.1159/000010093.

DOI:10.1159/000010093

PMID:10087416

Abstract

To assess the utility of new markers in monitoring bone turnover during treatment with GnRH agonists, alkaline phosphatase (total and bone specific) and urinary N-telopeptides were measured. 16 women undergoing treatment with GnRH agonists for endometriosis or leiomyomas were studied before and 3 months after the onset of treatment. N-telopeptide levels increased significantly (44% of baseline, p < 0.05). Bone specific alkaline phosphatase (BALP), measured with a new ELISA assay, was more elevated (40% of baseline, p = 0.001) than total ALP (15% of baseline, p < 0.001). In conclusion, in estrogen deficiency states, urinary N-telopeptide measurements provide a quantitative measure of bone resoption. In the assessment of bone formation, BALP determination is move sensitive than total ALP and this may be clinically useful.

摘要

为评估新标志物在促性腺激素释放激素（GnRH）激动剂治疗期间监测骨转换的效用，对碱性磷酸酶（总碱性磷酸酶和骨特异性碱性磷酸酶）和尿N-端肽进行了测量。对16名因子宫内膜异位症或平滑肌瘤接受GnRH激动剂治疗的女性在治疗开始前及治疗开始3个月后进行了研究。N-端肽水平显著升高（为基线水平的44%，p<0.05）。采用新型酶联免疫吸附测定法测得的骨特异性碱性磷酸酶（BALP）升高幅度更大（为基线水平的40%，p = 0.001），高于总碱性磷酸酶（为基线水平的15%，p<0.001）。总之，在雌激素缺乏状态下，尿N-端肽测量可提供骨吸收的定量指标。在评估骨形成时，BALP测定比总碱性磷酸酶更敏感，这可能具有临床应用价值。